Scarica l'app Stockscreener
162.71
183.71%
105.36
Dopo l'orario di chiusura:
171.75
9.04
+5.56%
Precedente Chiudi:
$57.35
Aprire:
$158.29
Volume 24 ore:
13.71M
Relative Volume:
20.88
Capitalizzazione di mercato:
$3.42B
Reddito:
$1.77M
Utile/perdita netta:
$-123.74M
Rapporto P/E:
-17.74
EPS:
-9.17
Flusso di cassa netto:
$-95.21M
1 W Prestazione:
+197.13%
1M Prestazione:
+287.40%
6M Prestazione:
+445.55%
1 anno Prestazione:
+119.70%
Intervallo 1D:
$156.41
$205.89
Intervallo di 1 settimana:
$50.56
$205.89
Portata 52W:
$26.70
$205.89
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Nome
Praxis Precision Medicines Inc
Settore
Industria
Telefono
617-300-8460
Indirizzo
99 HIGH STREET, 30TH FLOOR, BOSTON
Confronta PRAX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
162.71 | 1.11B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-03 | Reiterato | H.C. Wainwright | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-08-05 | Iniziato | Oppenheimer | Outperform |
| 2024-06-24 | Iniziato | Needham | Buy |
| 2024-06-18 | Iniziato | Guggenheim | Buy |
| 2024-05-01 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-19 | Iniziato | Truist | Buy |
| 2022-06-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-26 | Iniziato | BofA Securities | Buy |
| 2021-04-26 | Iniziato | William Blair | Outperform |
| 2020-11-11 | Iniziato | Wedbush | Outperform |
| 2020-11-10 | Iniziato | Cowen | Outperform |
| 2020-11-10 | Iniziato | Evercore ISI | Outperform |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie
Praxis Precision Medicines (PRAX) Stock Skyrockets 180% on Game‑Changing Trial – Analysts See 'Blockbuster' Upside - ts2.tech
Praxis Has Unexpected Hits In Two Phase II Essential Tremor Studies - insights.citeline.com
Praxis Precision (PRAX) Targets $400M Through Share and Warrant Sale - GuruFocus
Praxis Precision Medicines stock soars as Oppenheimer raises price target on trial success - Investing.com Nigeria
Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing. - MSN
PRAX: Jefferies Analyst Significantly Raises Price Target to $300 | PRAX Stock News - GuruFocus
Praxis Precision (PRAX) Announces Public Offering of Common Stock - GuruFocus
Praxis Precision Medicines announces proposed public offering - Investing.com
TSMC, Salesforce, HPE, F5, United Airlines, Travelers, J.B. Hunt, Praxis Precision, and More Movers - Barron's
Praxis Precision Medicines, Inc. Announces Proposed Public Offering - GlobeNewswire
Praxis Precision surges, analysts see ‘blockbuster potential’ for ulixacaltamide - Investing.com
Promising Potential of Praxis Precision Medicines: Buy Rating on Ulixacaltamide’s Strong Phase 3 Results and Market Opportunity - TipRanks
Praxis Precision Medicines’ Tremor Treatment is Back From the Dead. The Stock Is Up 200% - Barron's
Truist Securities raises Praxis Precision Medicines stock price target to $360 on positive trial results - Investing.com Canada
Praxis Precision Medicines stock price target raised to $251 by TD Cowen - Investing.com UK
Praxis Precision Medicine (PRAX): Analyst Raises Price Target by 212.5% | PRAX Stock News - GuruFocus
Baird raises Praxis Precision Medicines stock price target to $275 on positive trial results - Investing.com
Praxis stock surges on late-stage trial win (PRAX:NASDAQ) - Seeking Alpha
Jefferies Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $300 - 富途牛牛
Trending Stocks Today | Praxis Precision Medicines Surges 213% - 富途牛牛
Optimistic Buy Rating for Praxis Precision Medicines Amid Positive Phase 3 Results and Strategic Advancements - TipRanks
The 'Groundbreaking' Results That Sent Praxis Precision Medicines Up 184% - inkl
This ‘Strong Buy’ Stock Has More Than Tripled Today. Should You Buy It Here? - Yahoo Finance
Guggenheim raises Praxis Precision Medicines stock price target to $350 on positive trial data - Investing.com
Praxis Precision Medicines stock jumps over 235% today- Here’s why investors are paying attention - The Economic Times
Praxis stock hikes over 130% after strong phase 3 - Daily Jang
Praxis Precision Medicines stock hits 52-week high at 158.29 USD - Investing.com
Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday - Benzinga
Praxis Precision Medicines Stock Soars 100% After Tremor Drug Shows Positive Results - parameter.io
Will Praxis Precision’s Momentum Endure? - StocksToTrade
PRAX Stock: Surge or Sputter? - timothysykes.com
Why Is Praxis Precision Medicines (PRAX) Stock Up 155% Today? - TipRanks
Praxis Precision Medicines Announces Positive Phase 3 Results - TipRanks
A longshot bet on a tremor drug pays off - Yahoo Finance
Praxis (PRAX) Soars on Successful Late-Stage Trials for Ulixacal - GuruFocus
Praxis Precision Medicines Stock DoublesHere's Why - Benzinga
Praxis Precision Medicines announces positive results from phase 3 studies - MarketScreener
PRAX Reports Positive Phase 3 Results for Ulixacaltamide in Esse - GuruFocus
Why Did Praxis Precision Medicines Stock Surge 69% In Pre-Market Today? - Stocktwits
Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor - GlobeNewswire
Praxis Precision Medicines stock soars after positive Phase 3 tremor drug results - Investing.com
Praxis Precision Medicines' movement disorder drug shows promise in trials - Yahoo
Can Praxis Precision Medicines Inc. stock deliver surprise earnings beatMarket Growth Review & Step-by-Step Trade Execution Guides - newser.com
Is Praxis Precision Medicines Inc. stock undervalued vs historical averagesJuly 2025 Sector Moves & Free Community Supported Trade Ideas - newser.com
Published on: 2025-10-15 05:17:04 - newser.com
How to track smart money flows in Praxis Precision Medicines Inc.Weekly Earnings Recap & Technical Entry and Exit Alerts - newser.com
How to use Fibonacci retracement on Praxis Precision Medicines Inc.July 2025 Short Interest & Accurate Buy Signal Alerts - newser.com
Price momentum metrics for Praxis Precision Medicines Inc. explained2025 Retail Activity & High Return Stock Watch Alerts - newser.com
Is a New ReCode Partnership Shaping the Investment Case for Praxis Precision Medicines (PRAX)? - simplywall.st
Multi asset correlation models including Praxis Precision Medicines Inc.Weekly Earnings Recap & Safe Entry Momentum Tips - newser.com
Praxis Precision Medicines (NASDAQ:PRAX) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Praxis Precision Medicines Inc Azioni (PRAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Praxis Precision Medicines Inc Azioni (PRAX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 14 '24 |
Option Exercise |
56.94 |
7,583 |
431,776 |
18,540 |
| Nemiroff Alex | General Counsel and Secretary |
Nov 14 '24 |
Sale |
80.20 |
8,239 |
660,827 |
10,301 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Option Exercise |
56.94 |
4,374 |
249,056 |
10,801 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Sale |
81.78 |
5,188 |
424,318 |
5,613 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):